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Abstract
Background: Brazil’s National Tuberculosis Control Program seeks to improve tuberculosis (TB) treatment in vulnerable
populations. Slum residents are more vulnerable to TB due to a variety of factors, including their overcrowded living
conditions, substandard infrastructure, and limited access to healthcare compared to their non-slum dwelling
counterparts. Directly observed treatment (DOT) has been suggested to improve TB treatment outcomes among
vulnerable populations, but the program’s differential effectiveness among urban slum and non-slum residents is not
known.
Methods: We retrospectively compared the impact of DOT on TB treatment outcome in residents of slum and non-slum
census tracts in Rio de Janeiro reported to the Brazilian Notifiable Disease Database in 2010. Patient residential addresses
were geocoded to census tracts from the 2010 Brazilian Census, which were identified as slum (aglomerados subnormais
-AGSN) and non-slum (non-AGSN) by the Census Bureau. Homeless and incarcerated cases as well as those geocoded
outside the city’s limits were excluded from analysis.
Results: In 2010, 6,601 TB cases were geocoded within Rio de Janeiro; 1,874 (27.4 %) were residents of AGSN,
and 4,794 (72.6 %) did not reside in an AGSN area. DOT coverage among AGSN cases was 35.2 % (n = 638),
while the coverage in non-AGSN cases was 26.2 % (n = 1,234). Clinical characteristics, treatment, follow-up,
cure, death and abandonment were similar in both AGSN and non-AGSN TB patients. After adjusting for
covariates, AGSN TB cases on DOT had 1.67 (95 % CI: 1.17, 2.4) times the risk of cure, 0.61 (95 % CI: 0.41, 0.90)
times the risk of abandonment, and 0.1 (95 % CI: 0.01, 0.77) times the risk of death from TB compared to non-AGSN TB
cases not on DOT.
Conclusion: While DOT coverage was low among TB cases in both AGSN and non-AGSN communities, it had a
greater impact on TB cure rate in AGSN than in non-AGSN populations in the city of Rio de Janeiro.
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Background
Between 1990 and 2012, the incidence of tuberculosis
(TB) in Brazil decreased by an average of 1.3 % each year.
Despite this decrease, the country remains one of twenty-
two World Health Organization (WHO) high-burden TB
countries [1]. Brazil also has a large urban slum popula-
tion (as defined by both the United Nations and the
Brazilian Census Bureau), where 11.4 million (6.0 %) of its
roughly 200 million people reside. Rio de Janeiro has the
nation’s largest slum population, with 1.4 million of the
city’s 6.3 million people (22 % of the population) residing
in these communities [2].
The Sistema de Informação de Agravos de Notificação
(SINAN) is Brazil's national Notifiable Disease Surveil-
lance System to which all TB cases are compulsorily
reported. The proportion of incident TB cases detected
by SINAN ranges from 85 to 90 % [1].
The Stop TB Partnership’s Global Plan to Stop TB has
as its primary goals to address HIV-related TB, limit the
spread and development of multidrug-resistant (MDR)
TB, and empower communities and vulnerable popula-
tions afflicted with TB [3]. To this end, in 2006 Brazil
augmented its National TB Control Program (NTCP) by
expanding the use of directly observed treatment (DOT)
and enhancing laboratory diagnostic capabilities [4].
In 2010, the burden of TB (measured in disability-
adjusted life years - DALY) was higher among residents
of Rio’s slums than among its non-slum residents [5].
While previous work has shown that DOT has been ef-
fectively implemented in vulnerable populations in Brazil
[6], a comparative analysis of the impact of DOT in
slums and formal communities has yet to be done. This
study examines the impact of DOT on TB treatment
outcome in these two types of neighborhood in the city
of Rio de Janeiro, Brazil.
Methods
This is a retrospective analysis of all TB cases (7,276) with
onset in 2010 that were reported to SINAN in Rio de
Janeiro, Brazil. The cases were geocoded by patient resi-
dential address with Google Geocoding API v.3 (https://
developers.google.com/maps/documentation/geocoding/
start) and mapped in ArcGIS 10 (ESRI, Redlands, CA,
USA). TB patients whose residences were outside of the
city limits (142, 2.0 %), who were incarcerated (452,
6.2 %), or were homeless (81, 1.1 %) were excluded.
The 2010 Census classified a census tract as “aglomer-
ados subnormal” or AGSN if the tract included a portion
(or all) of a community of at least 51 homes that illegally
occupied the land (i.e. was constructed on the property
of others) or received a land title in the previous ten
years) and at least one of the following: 1) a general scar-
city of public services or 2) construction outside of exist-
ing municipal patterns [2]. TB cases in the SINAN
database were overlaid and mapped on the census tract
shapefiles from the 2010 Brazilian Census. Individuals
with TB who lived in or within 50 meters of an AGSN
census tract were identified as slum TB cases.
Demographic (age, sex), clinical characteristics (pulmon-
ary or extrapulmonary, relapse or not), TB diagnostic re-
sults (tuberculin skin test and acid-fast bacilli smear
results), treatment (DOT, time from diagnosis until no-
tification) and follow-up (contact tracing) were compared
between slum (AGSN) and non-slum (non-AGSN) TB
cases in the city. Analyses were performed in Stata 12.1
(Statacorp, College Station, USA).
TB treatment outcomes were consistent with the
Brazilian Ministry of Health’s definitions [7]. Cure was
defined as two consecutively negative sputum smears, one
before and one after cessation of chemotherapy. Treat-
ment abandonment was defined as a patient’s absence
from the treatment center for a minimum of 30 days after
the return date indicated by his or her health professional.
TB treatment outcomes (including mortality) are reported
to and updated in the SINAN database by health profes-
sionals at the health unit where treatment occurs.
Health professionals at the primary health units where
suspected TB patients are first encountered report all new
TB cases to SINAN using a standardized case notification
form. These suspected cases are prospectively followed
until the case is considered closed with one of the follow-
ing outcomes: cure, abandonment, death from TB, death
from other cause, transfer, or missing outcome.
In Brazil, DOT is implemented in accordance with
WHO recommendations [8], by the country’s primary
health system (Sistema Único de Saúde - SUS). The pa-
tient appears at the treatment center a minimum of three
times each week during the first two months of treatment,
or has the same frequency of home visits by community
health workers [7]. The Brazilian Ministry of Health’s pol-
icy is that all TB cases (new and reactivation TB) should
receive DOT. In practice, health professionals use DOT
for patients perceived as being at greatest risk of treatment
failure. The decision to observe treatment at home or at
the health clinic is made by the health professional in con-
sultation with the patient. This policy also alludes to the
importance of making this decision given existing limita-
tions in infrastructure or availability of human resources
(e.g. if there are enough employees to observe treatment,
or if a health unit is geographically proximal to the pa-
tient) [7]. In Brazil, provision of food and transportation
vouchers for those enrolled in DOT is at the discretion of
individual health professionals and encouraged by the
Ministry of Health when a professional believes it will en-
hance treatment adherence [9].
We assessed differences in the demographic and socio-
economic characteristics of TB cases in AGSN and non-
AGSN areas using the Mantel-Haenszel (MH) chi-
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squared test and Students T-test where appropriate. We
calculated relative risks (RR) with the Mantel-Haenszel
(MH) chi-squared test for treatment outcomes (e.g.
death, cure rate, abandonment, transfer, etc.) in those
who did or did not undergo DOT to compare treatment
outcomes of TB cases on DOT versus treatment out-
comes of TB cases not on DOT.
After this crude analysis, multivariable logistic regres-
sion models were developed to adjust for other factors
that may have influenced the relationship between DOT,
AGSN residence, and TB treatment outcomes: cure,
abandonment, and death from TB. Those who trans-
ferred elsewhere for treatment (590, 8.9 %) or were miss-
ing treatment outcome data (688, 10.4 %) were excluded
from all models, leaving 5,266 (80.7 %) eligible TB cases.
Potential confounding variables were included if they
were related to TB treatment outcome. Those available
in SINAN include: age, sex, HIV status, alcoholism, dia-
betes, relapse (a TB case that was previously declared
cured), and disease severity (extrapulmonary v. pulmon-
ary), in addition to DOT status, and residence in an
AGSN [10–12]. Models were created in a forward step-
wise process, maintaining covariates in the final models
with p-values less than 0.20. Dummy variables were cre-
ated to test for interaction between age and sex, as well
as DOT and residence in a slum. Using these dummy
variables, we evaluated the hypothesis that DOT treat-
ment varied in effectiveness between AGSN and non-
AGSN TB cases [13, 14].
Results
In 2010, there were 1,807 TB cases among residents of
AGSN areas (0.13 % of the total AGSN population,
27.4 % of all TB cases in Rio de Janeiro in 2010), and
4,794 cases among residents of non-AGSN areas in Rio
de Janeiro (0.10 % of the total non-AGSN population,
76.2 % of 2010 Rio TB cases) that were reported to
SINAN (Table 1). Among all covariates, the average pro-
portion of missing covariates for eligible participants
was 0.21 %. Of 6,601 total TB cases, 2,317 (35.1 %) were
in women. The mean age of all TB cases was 38.7 years
(standard deviation: 16.5).
Of the 1,807 cases living in AGSN areas 638 (35.2 %)
were on DOT while 1,234 (26.2 %) TB patients living in
non-AGSN areas were on DOT. Among TB patients liv-
ing in AGSN areas, 963 (56.7 %) patients were cured,
while 2,622 (57.8 %) TB patients living outside of AGSN
areas were cured (Table 2). Of 1,807 AGSN TB patients,
325 (19.1 %) abandoned treatment, and 746 (16.5 %)
non-AGSN TB patients did so (Table 2). Among AGSN
TB patients, 32 (1.9 %) died from other causes while 68
(4.0 %) died from TB. Of the non-AGSN cases, 128
(2.8 %) died from other causes while 199 (4.4 %) died
from TB. Among AGSN TB cases, 17 (2.7 %) on DOT
died of all causes, while among non-AGSN cases 52
(4.2 %) not on DOT and 275 (8.4 %) on DOT died of all
causes.
Unadjusted bivariate analyses indicated that those liv-
ing in AGSN and on DOT were 1.66 (95 % confidence
interval (CI): 1.45-1.91) times as likely to be cured and
had 0.20 (95 % CI: 0.08-0.46) times the risk of death
compared to those not on DOT in AGSN. Outside of
AGSN, those on DOT had 1.15 (95 % CI: 1.04-1.27)
times the probability of cure and 0.54 (95 % CI: 0.38-
0.76) times the risk of death compared to those not
on DOT. Of those on DOT in AGSN, 118 (18.5 %)
abandoned treatment, while 265 (21.5 %) non-AGSN
patients did so. Those who transferred to another
municipality for TB treatment or who were missing
their treatment outcome were not more likely to be
residents of an AGSN.
Holding other factors constant (age, sex, HIV/AIDS
and clinical disease presentation - pulmonary v. extra-
pulmonary), TB cases residing in AGSN areas were less
likely to be cured (0.77, 95 % CI: 0.63-0.95) than TB
cases living outside of AGSN areas (Table 3). TB cases
on DOT and living outside of AGSN were 1.16 times as
likely to be cured (95 % CI: 0.95-1.42) as TB cases not
on DOT living outside of AGSN. However, if the TB
case was a resident of an AGSN area and on DOT, the
chance of cure increased to 1.67 (95 % CI: 1.17-2.40)
compared to TB cases that were not residents of AGSN
and not on DOT.
The risk of treatment abandonment was similarly
influenced by DOT and the TB case’s location of
residence. Controlling for sex, age, clinical disease
severity, and HIV/AIDS, we found that TB patients
that resided in an AGSN were 1.33 times more likely
to abandon treatment (95 % CI: 1.05-1.67) (Table 3)
than TB patients not residing in an AGSN. Being on
DOT did not have a statistically significant effect on risk
of treatment abandonment (1.15; 95 % CI: 0.92-1.43).
However, TB cases residing in an AGSN area and on
DOT had 0.61 times the risk of abandonment (95 %
CI: 0.41-0.90) compared to TB cases not in AGSN
and not on DOT.
Similarly, the relationship between a TB case being
on DOT and dying from TB was also modified by
whether or not the case resided in an AGSN area
(Table 3). When controlling for age, clinical disease se-
verity, and HIV/AIDS, being on DOT decreased the
risk of death from TB by a factor of 0.39 (95 % CI:
0.23-0.67). Being a resident of an AGSN did not signifi-
cantly increase the risk of death from TB (1.23, 95 %
CI: 0.85, 1.78). Being on DOT and residing in an AGSN
area reduced the risk of death from TB by a factor of
0.1 (95 % CI: 0.01, 0.77) compared to not being on
DOT and not residing in an AGSN.
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Discussion
Slum-defining characteristics, such as overcrowding, poor
access to healthcare, and poverty are associated with worse
TB treatment completion and disease outcomes [15, 16].
Here, we found that DOT administered to TB patients liv-
ing in Rio de Janeiro, Brazil's informal settlements (AGSN)
Table 1 Slum (aglomerados subnormais - AGSN) and non-slum (non-AGSN) tuberculosis clinical and treatment characteristics, Rio de
Janeiro, Brazil, 2010
Total n (%) Slum n (%) Non-slum n (%) P-value*
Number of cases 6601 (100.0) 1807 (27.4) 4794 (72.6) -
Median age (IQR) 37 (26, 50) 38 (37, 51) 33 (23, 47) -
Sex (% female) 2317 (35.1) 1666 (34.8) 651 (36.0) 0.313
Site of TB
Pulmonary 5412 (82.0) 1515 (83.8) 3897 (81.3) 0.02
Extrapulmonary 867 (13.1) 218 (12.1) 649 (13.5) 0.11
Pulmonary and extrapulmonary 322 (4.9) 74 (4.1) 248 (5.2) 0.07
Case category
New case 5173 (78.4) 1362 (75.4) 3811 (79.5) <0.001
Relapse after previous treatment completion 483 (7.3) 167 (9.2) 316 (6.6) <0.001
Relapse after loss to follow-up in previous treatment 545 (8.3) 177 (9.8) 368 (7.7) 0.01
Unknown 73 (1.1) 16 (0.89) 57 (1.2) 0.29
Transfer to other municipality 327 (5.0) 85 (4.7) 242 (5.1) 0.57
Tuberculin skin test result
Not reactive (0-4 mm) 266 (4.0) 57 (3.2) 209 (4.4) 0.03
Weak reaction (5-9 mm) 101 (1.5) 33 (1.8) 68 (1.4) 0.23
Strong reaction (≥10 mm) 638 (9.7) 175 (9.7) 463 (9.7) 0.97
Not performed 5590 (84.7) 1542 (85.3) 4048 (84.4) 0.37
Acid-fast bacilli smear at diagnosis
Positive 3228 (48.9) 959 (53.1) 2269 (47.3) <0.01§
Negative 1551 (23.5) 368 (20.4) 1183 (24.7)
Not performed 1822 (27.6) 480 (26.6) 1342 (28.0)
Indicated for DOT at diagnosis
Yes; completed full course 1892 (28.7) 636 (35.2) 1256 (26.2) <0.01†
Yes; did not complete full course 10 (0.2) 10 (0.6) -
No 4410 (66.8) 1081 (59.8) 3329 (69.4)
Unknown 289 (4.4) 80 (4.4) 209 (4.4)
Treatment changed due to intolerance or failure
Yes 45 (0.7) 17 (0.9) 28 (0.6) 0.12
No/not recorded 6556 (99.3) 1709 (99.1) 4766 (99.4)
All contacts indicated at diagnosis examined at follow-up
Yes 3349 (51.2) 855 (47.8) 2494 (52.5) <0.01
No 3195 (48.8) 935 (52.2) 2260 (47.5)
Median days (IQR) from diagnosis until notification 0 (0, 14) 0 (0, 14) 1 (0, 14) -
Median days (IQR) from diagnosis until initiation of treatment 0 (0,0) 0 (0, 0) 0 (0, 1) -
Median days (IQR) from initiation of treatment until change
of treatment due to adverse reaction
175 (77, 238) 182 (79.5, 237.5) 149 (76, 244) -
Median days (IQR) from diagnosis until end of follow-up 187 (145, 219) 187 (146, 218) 189 (145, 221) -
IQR interquartile range, 25th and 75th percentile
*P-value calculated to compare selected characteristics between cases in slums versus and non-slums
§Comparing positive versus negative AFB smear diagnosis
†Comparing all those assigned to DOT (regardless of completion)
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Table 3 Logistic regression models predicting risk of cure (model 1), abandonment of treatment (model 2) and death (model 3)
from tuberculosis among all TB cases in Rio de Janeiro, Brazil, 2010
Odds ratio Standard error 95 % confidence interval
Model 1: risk of cure*
On directly observed treatment (DOT) 1.16 0.12 0.95, 1.42
Residence in a slum (AGSN) area 0.77 0.08 0.63, 0.95
Sex (reference female) 0.73 0.06 0.62, 0.85
Age in years 1.01 0.002 1.00, 1.01
Extrapulmonary clinical disease 2.07 0.23 1.66, 2.59
HIV/AIDS 0.23 0.02 0.19, 0.28
DOT x AGSN (interaction term) 1.67 0.31 1.17, 2.40
Model 2: risk of abandonment§
On directly observed treatment (DOT) 1.15 0.13 0.92, 1.43
Residence in a slum (AGSN) area 1.33 0.16 1.05, 1.67
Sex (reference female) 1.41 0.13 1.18, 1.69
Age in years 0.98 0.003 0.97, 0.98
Extrapulmonary clinical disease 0.44 0.06 0.33, 0.57
HIV/AIDS 1.97 0.23 1.56, 2.48
DOT x AGSN (interaction term) 0.61 0.12 0.41, 0.90
Model 3: risk of death†
On directly observed treatment (DOT) 0.39 0.11 0.23, 0.67
Residence in a slum (AGSN) area 1.23 0.23 0.85, 1.78
Age in years 1.03 0.01 1.02, 1.04
Extrapulmonary clinical disease 0.64 0.13 0.43, 0.95
HIV/AIDS 8.79 1.45 6.35, 12.16
DOT x AGSN (interaction term) 0.10 0.10 0.01, 0.77
AGSN aglomerados subnormais
*N: 3797, R2 = 0.061
§N: 3797, R2 = 0.047
†N: 3797, R2 = 0.175
Table 2 Comparison of tuberculosis treatment outcome between patients receiving and not receiving directly observed treatment,
separated by census tract of residence: slum (aglomerados subnormais - AGSN) and non-slum (non-AGSN), Rio de Janeiro, Brazil, 2010
AGSN Non-AGSN P-value†
DOT (%) RR§ 95 % CI DOT (%) RR§ 95 % CI
Total Yes No Total Yes No
Missing outcome 174 (10.2) 39 (6.1) 135 (12.7) 0.56 0.42-0.74 462 (10.2) 98 (7.9) 364 (11.0) 0.77 0.64-0.92 0.06
Cure 963 (56.7) 430 (67.4) 533 (50.1) 1.66 1.45-1.91 2622 (57.8) 758 (61.4) 1864 (56.5) 1.15 1.04-1.27 <0.01
Abandonment 325 (19.1) 118 (18.5) 207 (19.5) 0.97 0.83-1.14 746 (16.5) 265 (21.5) 481 (14.6) 1.37 1.23-1.53 <0.01
Death TB 68 (4.0) 8 (1.3) 60 (5.6) 0.20 0.08-0.46 199 (4.4) 28 (2.3) 171 (5.2) 0.54 0.38-0.76 0.03
Death other 32 (1.9) 9 (1.4) 23 (2.2) 0.68 0.37-1.24 128 (2.8) 24 (1.9) 104 (3.2) 0.65 0.45-0.95 0.92
Transfer out 140 (8.2) 34 (5.3) 106 (10.0) 0.57 0.41-0.78 378 (8.3) 61 (4.9) 317 (9.6) 0.60 0.47-0.75 0.82
*There were 88 (4.4 %) cases in AGSN and 219 (4.4 %) outside of AGSN where the case’s DOT status was unknown
§Relative risk (RR) estimating crude risk of outcome in patients undergoing DOT compared to patients not undergoing DOT in slum versus
non-slum neighborhood
†P-values assessing for effect measure modification of AGSN census tracts on the relationship between DOT and respective outcome with the Mantel-Haenszel
chi-square test
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lowered a TB cases’ risk of treatment abandonment, or
death from TB, and increased the chance of being cured.
The Brazilian NTCP makes explicit its prioritization of
DOT in vulnerable populations, but has yet to adapt these
policies to residents of slums. The differential effectiveness
of DOT inside and outside of AGSN in Rio de Janeiro
highlighted here, lends support to the hypothesis that resi-
dents of slums should be considered a vulnerable popula-
tion when considering DOTas a treatment strategy for TB.
In Rio de Janeiro in 2010, DOT coverage was higher
among AGSN TB cases (35.2 %) than in non-AGSN TB
cases (26.2 %). Cure rates, however, remained low in
both communities. The TB cure rates inside (56.7 %)
and outside of AGSN (57.8 %) were nearly identical, and
roughly the same as the 2010 Brazilian average (61.9 %),
which is well below the Millennium Development Goal
of 85 % cure [1]. However, patients on DOT residing in
AGSN areas had better outcomes than patients on DOT
outside of AGSN areas. Within AGSN areas, TB cases
were 1.67 (95 % CI: 1.17-2.40) times more likely to be
cured if on DOT, compared to cases not on DOT and
not living in AGSN areas. In AGSN, the proportion of
deaths due to TB was 4.3 times higher among those who
were not on DOT, while it was 2.3 times higher in the
non-AGSN population not on DOT (Table 2).
Although treatment abandonment was higher in AGSN
than non-AGSN patients, abandonment by those on DOT
was less likely among TB patients living in AGSN areas
(18.5 %) than among TB patients not living in AGSN areas
(21.5 %). The higher rates of treatment abandonment
among those on DOT may be biased by the program’s de-
sign, as it is strongly encouraged as a treatment option for
those considered at risk for abandoning treatment.
Importantly, the provision of food and transport
vouchers is not noted in the SINAN database (a practice
encouraged to reduce abandonment). A 2015 survey of
health professionals from five different regions in Brazil
(not including Rio de Janeiro) indicated that only 51 %
and 20.5 % of surveyed clinics had access to food and
transport vouchers, respectively. It is possible that these
vouchers are more frequently given to TB cases that res-
ide in slums to discourage their risk of treatment aban-
donment while on DOT, but we cannot evaluate this
bias due to the absence of these data in SINAN [9].
Almost 5 % (289) of the SINAN database is lacking data
on DOT. In contrast to the observational data presented
here, a 2015 Cochrane meta-analysis of DOT randomized
control trials found questionable improvements in TB
outcome, highlighting the need to indicate where DOT is
administered (home or health facility) and who observes
treatment (family member or health professional) [17].
Completing these missing data, including the 10 % of
cases that were missing data on treatment outcome, and
simultaneously augmenting the SINAN database by
including location of DOT, and who is observing treat-
ment could further clarify how DOT works.
Of more concern is the fraction of data that are miss-
ing for other important covariates. Almost a quarter of
the 2010 TB cases (25.63 %) did not have their HIV sta-
tus recorded in SINAN despite the fact that HIV status
was the most important risk factor for cure, risk, and
abandonment. Health professionals must continue to
make efforts to identify all HIV-positive TB patients and
reliably report their HIV-status to SINAN.
There are several possible explanations for the apparent
greater impact of DOT on TB cases in AGSN. The pro-
gram is overseen by SUS’s community-based health pro-
gram, in which residents of the community where the
primary health centers are located serve as that health
center's community-health workers. The familiarity of
these agents with their patients and communities could
have contributed to the differential success of DOT in
AGSN. The quality of DOT coverage, therefore, may have
differed between the two populations.
This analysis is based on data from SINAN, which has a
high case-detection rate, but that relies on cases being
reported [1]. A 2008 study in Rio de Janeiro found that
roughly half of the city's TB deaths were not reported to
SINAN [18]. This was likely due to the severity of the
disease when it was diagnosed (i.e. patients who died and
were included in the mortality database but not in SINAN
were already at an advanced stage of disease when admitted
to the hospital and died before they were reported to
SINAN). Inclusion of data from the city’s mortality database
in this analysis would have increased the number of deaths,
but likely would not have influenced the differential influ-
ence of DOT in AGSN.
Case reporting and reliability of the database must be
enhanced so that the effectiveness of DOT can be thor-
oughly evaluated. The differential effect of DOT on TB
cases residing in AGSN areas should be confirmed in fu-
ture analyses as the quality of data reporting in SINAN
continues to improve. These findings suggest that DOT
should be more thoroughly implemented both inside
and outside of slums. The relatively greater effectiveness
of DOT within slums further emphasizes the importance
of identifying which TB cases reside in slums.
Conclusions
There were no notable differences in treatment between
AGSN and non-AGSN TB cases in Rio de Janeiro. TB
treatment outcomes were worse among TB cases not on
DOT, with DOT demonstrating the greatest impact on cure
rates in vulnerable AGSN communities. Our results suggest
an effect of DOT on mortality as well. The Brazilian NTCP’s
success with DOT in the AGSN communities of Rio de
Janeiro offers an established model for improving TB care
in vulnerable slum populations in other global megacities.
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